{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T21:14:10Z","timestamp":1792876450492,"version":"4.5.0"},"reference-count":98,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1016\/j.ygyno.2013.05.021","type":"journal-article","created":{"date-parts":[[2013,5,23]],"date-time":"2013-05-23T15:06:03Z","timestamp":1369321563000},"page":"660-666","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":53,"title":["Low-grade serous carcinoma: New concepts and emerging therapies"],"prefix":"10.1016","volume":"130","author":[{"given":"Ignacio","family":"Romero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte C.","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwong K.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Robert C.","family":"Bast","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Gershenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.ygyno.2013.05.021_bb0005","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1200\/JCO.2008.19.1684","article-title":"Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup","volume":"27","author":"Bookman","year":"2009","journal-title":"J Clin Oncol"},{"issue":"7353","key":"10.1016\/j.ygyno.2013.05.021_bb0010","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","author":"Cancer Genome Atlas Research Network","year":"2011","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.ygyno.2013.05.021_bb0015","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1097\/IGC.0b013e31821b2568","article-title":"2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference","volume":"21","author":"Stuart","year":"2011","journal-title":"Int J Gynecol Cancer"},{"issue":"6","key":"10.1016\/j.ygyno.2013.05.021_bb0020","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s11912-008-0078-8","article-title":"Low-grade serous ovarian cancer: a unique disease","volume":"10","author":"Schmeler","year":"2008","journal-title":"Curr Oncol Rep"},{"issue":"6","key":"10.1016\/j.ygyno.2013.05.021_bb0025","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1002\/cncr.24926","article-title":"The heterogeneity of epithelial ovarian cancer: getting it right","volume":"116","author":"Gershenson","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2013.05.021_bb0030","first-page":"921","article-title":"Relative frequency of primary ovarian neoplasms: a 10-year review","volume":"74","author":"Koonings","year":"1989","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ygyno.2013.05.021_bb0035","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/01.pgp.0000101080.35393.16","article-title":"The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin","volume":"23","author":"Seidman","year":"2004","journal-title":"Int J Gynecol Pathol"},{"issue":"4","key":"10.1016\/j.ygyno.2013.05.021_bb0040","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1093\/ajcp\/93.4.457","article-title":"Ovarian carcinomas with transitional cell carcinoma pattern","volume":"93","author":"Silva","year":"1990","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.ygyno.2013.05.021_bb0045","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1097\/00000478-200404000-00004","article-title":"Transitional cell carcinoma of the ovary: a morphologic study with emphasis on differential diagnosis","volume":"28","author":"Eichhorn","year":"2004","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ygyno.2013.05.021_bb0050","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1097\/00004347-200001000-00003","article-title":"Histopathologic grading of ovarian carcinoma: a review and proposal","volume":"19","author":"Silverberg","year":"2000","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.ygyno.2013.05.021_bb0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/00016347109157278","article-title":"Classification and staging of malignant tumors in the female pelvis","volume":"50","author":"International Federation of Gynecology and Obstetrics (FIGO)","year":"1971","journal-title":"Acta Obstet Gynecol Scand"},{"key":"10.1016\/j.ygyno.2013.05.021_bb0060","series-title":"in collaboration with Sobin LH and pathologists from 5 countries. World Health Organization Classification of Tumors: Pathology and Genetics of Tumors of the Breast and Female Genital Organs","first-page":"117","article-title":"Surface epithelial-stromal tumors: serous tumors","author":"Lee","year":"2003"},{"key":"10.1016\/j.ygyno.2013.05.021_bb0065","series-title":"Pathology of the female reproductive tract","first-page":"539","article-title":"Epithelial\/stromal tumors: serous tumors","author":"Russell","year":"2002"},{"key":"10.1016\/j.ygyno.2013.05.021_bb0070","series-title":"Tumors of the ovary, maldeveloped gonads, fallopian tube and broad ligament: Atlas of Tumor Pathology, 3rd series, fascicle 23","first-page":"51","article-title":"Surface epithelial-stromal tumors: serous tumors","author":"Scully","year":"1998"},{"key":"10.1016\/j.ygyno.2013.05.021_bb0075","series-title":"Blaunstein's pathology of the female genital tract","first-page":"791","article-title":"Surface epithelial tumors of the ovary","author":"Seidman","year":"2001"},{"key":"10.1016\/j.ygyno.2013.05.021_bb0080","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1097\/00000478-200404000-00009","article-title":"Grading ovarian serous carcinoma using a two-tier system","volume":"28","author":"Malpica","year":"2004","journal-title":"Am J Surg Pathol"},{"issue":"8","key":"10.1016\/j.ygyno.2013.05.021_bb0085","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1097\/PAS.0b013e31803199b0","article-title":"Interobserver and intraobserver variability of a two-tier system for grading ovarian serous carcinoma","volume":"31","author":"Malpica","year":"2007","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ygyno.2013.05.021_bb0090","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1002\/(SICI)1097-0142(19980301)82:5<893::AID-CNCR14>3.0.CO;2-W","article-title":"Toward the development of a universal grading system for ovarian epithelial carcinoma: testing of a proposed system in a series of 461 patients with uniform treatment and follow-up","volume":"82","author":"Shimizu","year":"1998","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.ygyno.2013.05.021_bb0095","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.ygyno.2006.05.030","article-title":"Testing of two binary grading systems for FIGO stage III serous carcinoma of the ovary and peritoneum","volume":"103","author":"Seidman","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2013.05.021_bb0100","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1097\/PAS.0b013e31816fd555","article-title":"Subdividing ovarian and peritoneal serous carcinoma into moderately differentiated and poorly differentiated does not have biologic validity based on molecular genetic and in vitro drug resistance data","volume":"32","author":"Vang","year":"2008","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ygyno.2013.05.021_bb0105","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1002\/cncr.26618","article-title":"Reclassification of serous ovarian carcinoma by a 2-tier system: a Gynecologic Oncology Group Study","volume":"118","author":"Bodurka","year":"2012","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.ygyno.2013.05.021_bb0110","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1097\/PAS.0b013e3181a24354","article-title":"Defining the cut point between low-grade and high-grade ovarian serous carcinomas: a clinicopathologic and molecular genetic analysis","volume":"33","author":"Ayhan","year":"2009","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ygyno.2013.05.021_bb0115","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0029-7844(01)01649-0","article-title":"Response and survival in patients with progressive or recurrent serous ovarian tumors of low malignant potential","volume":"99","author":"Crispens","year":"2002","journal-title":"Obstet Gynecol"},{"issue":"6","key":"10.1016\/j.ygyno.2013.05.021_bb0120","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1097\/PGP.0b013e3181e31f74","article-title":"Patterns of low-grade serous carcinoma with emphasis on the nonepithelial-lined spaces pattern of invasion and the disorganized orphan papillae","volume":"29","author":"Silva","year":"2010","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.ygyno.2013.05.021_bb0125","series-title":"World Health Organisation classification of tumors. Pathology and genetics. Tumors of the breast and female genital organs","first-page":"119","article-title":"Serous tumors. In tumors of the ovary and peritoneum","author":"Tavassoli","year":"2003"},{"key":"10.1016\/j.ygyno.2013.05.021_bb0130","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1053\/hp.2000.8048","article-title":"Ovarian serous borderline tumors a critical review of the literature with emphasis on prognostic indicators","volume":"31","author":"Seidman","year":"2000","journal-title":"Hum Pathol"},{"key":"10.1016\/j.ygyno.2013.05.021_bb0135","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1097\/01.pas.0000164030.82810.db","article-title":"Ovarian serous tumors of low malignant potential (borderline tumors): outcome-based study of 276 patients with long-term (5-year) follow-up","volume":"29","author":"Longacre","year":"2005","journal-title":"Am J Surg Pathol"},{"issue":"10","key":"10.1016\/j.ygyno.2013.05.021_bb0140","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1097\/01.pas.0000213299.11649.fa","article-title":"Patterns of stromal invasion in ovarian serous tumors of low malignant potential (borderline tumors): a reevaluation of the concept of stromal microinvasion","volume":"30","author":"McKenney","year":"2006","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"10.1016\/j.ygyno.2013.05.021_bb0145","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ejogrb.2009.04.031","article-title":"Long-term follow-up after ovarian borderline tumor: relapse and survival in a large patient cohort","volume":"145","author":"Lenhard","year":"2009","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"1","key":"10.1016\/j.ygyno.2013.05.021_bb0150","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ygyno.2007.01.054","article-title":"Microinvasion links ovarian serous borderline tumor and grade 1 invasive carcinoma","volume":"106","author":"Hogg","year":"2007","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2013.05.021_bb0155","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1097\/00000478-199611000-00003","article-title":"Micropapillary serous carcinoma of the ovary: a distinctive low-grade carcinoma related to serous borderline tumors","volume":"20","author":"Burks","year":"1996","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ygyno.2013.05.021_bb0160","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1097\/00000478-199611000-00004","article-title":"Subclassification of serous borderline tumors of the ovary into benign and malignant types: a clinicopathologic study of 65 advanced stage cases","volume":"20","author":"Seidman","year":"1996","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ygyno.2013.05.021_bb0165","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1097\/00000478-199904000-00004","article-title":"Ovarian serous borderline tumors with micropapillary and cribriform patterns: a study of 40 cases and comparison with 44 cases without these patterns","volume":"23","author":"Eichhorn","year":"1999","journal-title":"Am J Surg Pathol"},{"issue":"9","key":"10.1016\/j.ygyno.2013.05.021_bb0170","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1097\/00000478-200209000-00003","article-title":"Micropapillary and cribriform patterns in ovarian serous tumors of low malignant potential: a study of 99 advanced stage cases","volume":"26","author":"Deavers","year":"2002","journal-title":"Am J Surg Pathol"},{"issue":"5","key":"10.1016\/j.ygyno.2013.05.021_bb0175","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1097\/CCO.0b013e32833b0dc1","article-title":"The pathology of and controversial aspects of ovarian borderline tumours","volume":"22","author":"McCluggage","year":"2010","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.ygyno.2013.05.021_bb0185","series-title":"Early stages (I\u2013IIa) epithelial ovarian cancer (EOC): preliminary data of the prospective register of the Spanish Group on Research of Ovarian cancer (GEICO)","author":"Ruiz","year":"2008"},{"key":"10.1016\/j.ygyno.2013.05.021_bb0190","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/00000478-200402000-00001","article-title":"Clinicopathologic analysis of early-stage sporadic ovarian carcinoma","volume":"28","author":"Leitao","year":"2004","journal-title":"Am J Surg Pathol"},{"issue":"24","key":"10.1016\/j.ygyno.2013.05.021_bb0195","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.1200\/JCO.2006.10.2517","article-title":"Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study","volume":"25","author":"Winter","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2013.05.021_bb0200","doi-asserted-by":"crossref","first-page":"459.e1","DOI":"10.1016\/j.ajog.2008.01.035","article-title":"Epidemiology of low-grade serous ovarian cancer","volume":"198","author":"Plaxe","year":"2008","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ygyno.2013.05.021_bb0210","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1002\/(SICI)1097-0142(19981115)83:10<2157::AID-CNCR14>3.0.CO;2-D","article-title":"Serous borderline tumors of the ovary with noninvasive peritoneal implants","volume":"83","author":"Gershenson","year":"1998","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2013.05.021_bb0215","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1002\/(SICI)1097-0142(19980315)82:6<1096::AID-CNCR13>3.0.CO;2-1","article-title":"Ovarian serous borderline tumors with invasive peritoneal implants","volume":"82","author":"Gershenson","year":"1998","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2013.05.021_bb0220","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1097\/01.pas.0000213294.81154.95","article-title":"The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent","volume":"11","author":"Silva","year":"2006","journal-title":"Am J Surg Pathol"},{"issue":"12","key":"10.1016\/j.ygyno.2013.05.021_bb0225","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1056\/NEJM199409223311204","article-title":"Ovarian tumors in a cohort of infertile women","volume":"331","author":"Rossing","year":"1994","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ygyno.2013.05.021_bb0230","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1006\/gyno.1997.4928","article-title":"Treatment for fertility and risk of ovarian tumors of borderline malignancy","volume":"68","author":"Parazzini","year":"1998","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.ygyno.2013.05.021_bb0235","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1159\/000316264","article-title":"Clinical recommendation on fertility preservation in borderline ovarian neoplasm: ovarian stimulation and oocyte retrieval after conservative surgery","volume":"70","author":"Denschlag","year":"2010","journal-title":"Gynecol Obstet Invest"},{"issue":"19","key":"10.1016\/j.ygyno.2013.05.021_bb0240","doi-asserted-by":"crossref","first-page":"6432","DOI":"10.1158\/1078-0432.CCR-04-0893","article-title":"Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas","volume":"10","author":"Hsu","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.ygyno.2013.05.021_bb0245","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1093\/jnci\/95.6.484","article-title":"Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma","volume":"95","author":"Singer","year":"2003","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"10.1016\/j.ygyno.2013.05.021_bb0250","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.ygyno.2006.05.029","article-title":"KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants","volume":"103","author":"Mayr","year":"2006","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.ygyno.2013.05.021_bb0255","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/path.1521","article-title":"In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours","volume":"202","author":"Sieben","year":"2004","journal-title":"J Pathol"},{"issue":"4","key":"10.1016\/j.ygyno.2013.05.021_bb0260","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/S0002-9440(10)62549-7","article-title":"Diverse tumorigenic pathways in ovarian serous carcinoma","volume":"160","author":"Singer","year":"2002","journal-title":"Am J Pathol"},{"issue":"1","key":"10.1016\/j.ygyno.2013.05.021_bb0265","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/00004347-200301000-00009","article-title":"Mutational analysis of K-ras segregates ovarian serous carcinomas into two types: invasive MPSC (low-grade tumor) and conventional serous carcinoma (high-grade tumor)","volume":"22","author":"Singer","year":"2003","journal-title":"Int J Gynecol Pathol"},{"issue":"2","key":"10.1016\/j.ygyno.2013.05.021_bb0270","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1097\/01.pas.0000146025.91953.8d","article-title":"Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation","volume":"29","author":"Singer","year":"2005","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"10.1016\/j.ygyno.2013.05.021_bb0275","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/00000478-199903000-00012","article-title":"Comparison of mutations of Ki-RAS and p53 immunoreactivity in borderline and malignant epithelial ovarian tumors","volume":"23","author":"Caduff","year":"1999","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"10.1016\/j.ygyno.2013.05.021_bb0280","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1373\/clinchem.2004.041194","article-title":"Biochip for K-ras mutation screening in ovarian cancer","volume":"51","author":"Fabjani","year":"2005","journal-title":"Clin Chem"},{"key":"10.1016\/j.ygyno.2013.05.021_bb0285","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/1471-2407-9-111","article-title":"KRAS mutation analysis in ovarian samples using a high sensitivity biochip assay","volume":"9","author":"Auner","year":"2009","journal-title":"BMC Cancer"},{"issue":"13","key":"10.1016\/j.ygyno.2013.05.021_bb0290","first-page":"3103","article-title":"p53 and Ki-ras gene mutations in epithelial ovarian neoplasms","volume":"53","author":"Teneriello","year":"1993","journal-title":"Cancer Res"},{"issue":"11","key":"10.1016\/j.ygyno.2013.05.021_bb0295","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1158\/1541-7786.MCR-08-0193","article-title":"Mutation of ERBB2 provides a novel alternative mechanism for the ubiquitous activation of RAS-MAPK in ovarian serous low malignant potential tumors","volume":"6","author":"Anglesio","year":"2008","journal-title":"Mol Cancer Res"},{"issue":"4","key":"10.1016\/j.ygyno.2013.05.021_bb0300","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.2353\/ajpath.2010.100212","article-title":"BRAF mutation is rare in advanced-stage low grade ovarian serous carcinomas","volume":"177","author":"Wong","year":"2010","journal-title":"Am J Pathol"},{"issue":"7353","key":"10.1016\/j.ygyno.2013.05.021_bb0305","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","volume":"474","author":"Cancer Genome Atlas Research Network","year":"2011","journal-title":"Nature"},{"issue":"5578","key":"10.1016\/j.ygyno.2013.05.021_bb0310","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1126\/science.1073096","article-title":"Cancer. Addiction to oncogenes \u2014 the Achilles heel of cancer","volume":"297","author":"Weinstein","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.ygyno.2013.05.021_bb0315","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/cncr.27782","article-title":"BRAF mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer","volume":"119","author":"Grisham","year":"2013","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.ygyno.2013.05.021_bb0320","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1002\/humu.9316","article-title":"PIK3CA mutations in advanced ovarian carcinomas","volume":"25","author":"Wang","year":"2005","journal-title":"Hum Mutat"},{"key":"10.1016\/j.ygyno.2013.05.021_bb0325","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/path.3967","article-title":"Low-grade serous carcinomas of the ovary contain very few point mutations","volume":"226","author":"Jones","year":"2012","journal-title":"J Pathol"},{"key":"10.1016\/j.ygyno.2013.05.021_bb0330","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/S0140-6736(09)60249-X","article-title":"Genomic copy number variation, human health, and disease","volume":"374","author":"Wain","year":"2009","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.ygyno.2013.05.021_bb0335","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.tig.2006.06.007","article-title":"Gene amplification in cancer","volume":"22","author":"Albertson","year":"2006","journal-title":"Trends Genet"},{"issue":"15","key":"10.1016\/j.ygyno.2013.05.021_bb0340","first-page":"4045","article-title":"Distinction of low-grade from high-grade human ovarian carcinomas on the basis of losses of heterozygosity on chromosomes 3, 6, 11 and HER-2\/neu gene amplification","volume":"51","author":"Zheng","year":"1991","journal-title":"Cancer Res"},{"issue":"22","key":"10.1016\/j.ygyno.2013.05.021_bb0345","doi-asserted-by":"crossref","first-page":"10602","DOI":"10.1158\/0008-5472.CAN-05-2240","article-title":"Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary","volume":"65","author":"Bonome","year":"2005","journal-title":"Cancer Res"},{"issue":"9","key":"10.1016\/j.ygyno.2013.05.021_bb0350","doi-asserted-by":"crossref","first-page":"4036","DOI":"10.1158\/0008-5472.CAN-08-3913","article-title":"Analysis of DNA copy number alterations in ovarian serous tumors identifies new molecular genetic changes in low-grade and high-grade carcinomas","volume":"69","author":"Kuo","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.ygyno.2013.05.021_bb0355","doi-asserted-by":"crossref","first-page":"e28250","DOI":"10.1371\/journal.pone.0028250","article-title":"Chromosome 3 anomalies investigated by genome wide SNP analysis of benign, low malignant potential and low-grade ovarian serous tumours","volume":"6","author":"Birch","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ygyno.2013.05.021_bb0360","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1038\/sj.onc.1208298","article-title":"Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential","volume":"24","author":"Meinhold-Heerlein","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/j.ygyno.2013.05.021_bb0365","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/mc.10098","article-title":"Molecular determination of tumor differentiation in papillary serous ovarian carcinoma","volume":"36","author":"Jazaeri","year":"2003","journal-title":"Mol Carcinog"},{"key":"10.1016\/j.ygyno.2013.05.021_bb0370","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1097\/01.pas.0000166367.68459.7d","article-title":"An immunohistochemical comparison between low-grade and high-grade ovarian serous carcinomas","volume":"29","author":"O'Neill","year":"2005","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"10.1016\/j.ygyno.2013.05.021_bb0375","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1097\/pgp.0b013e31803025cd","article-title":"Significantly greater expression of ER, PR, and ECAD in advanced-stage low-grade ovarian serous carcinoma as revealed by immunohistochemical analysis","volume":"26","author":"Wong","year":"2007","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.ygyno.2013.05.021_bb0380","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1038\/modpathol.2009.92","article-title":"PAX2 expression in low malignant ovarian tumors and low-grade ovarian serous carcinomas","volume":"22","author":"Tung","year":"2009","journal-title":"Mod Pathol"},{"key":"10.1016\/j.ygyno.2013.05.021_bb0385","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1097\/PAS.0b013e318212ae22","article-title":"The anterior gradient homolog 3 (AGR3) gene is associated with differentiation and survival in ovarian cancer","volume":"35","author":"King","year":"2011","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ygyno.2013.05.021_bb0390","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ygyno.2011.06.016","article-title":"The insulin-like growth factor 1 pathway is a potential therapeutic target for low-grade serous ovarian carcinoma","volume":"123","author":"King","year":"2011","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2013.05.021_bb9000","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ygyno.2010.01.006","article-title":"Low malignant potential tumors with micropapillary features are molecularly similar to low-grade serous carcinoma of the ovary","volume":"117","author":"May","year":"2010","journal-title":"Gynecol Oncol"},{"issue":"5","key":"10.1016\/j.ygyno.2013.05.021_bb0395","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/nrc1611","article-title":"Ovarian cancer metastasis: integrating insights from disparate model organisms","volume":"5","author":"Naora","year":"2005","journal-title":"Nat Rev Cancer"},{"issue":"7716","key":"10.1016\/j.ygyno.2013.05.021_bb0400","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0140-6736(71)92335-X","article-title":"Incessant ovulation \u2014 a factor in ovarian neoplasia?","volume":"2","author":"Fathalla","year":"1971","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ygyno.2013.05.021_bb0405","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1006\/gyno.1994.1037","article-title":"Overexpression of p53 is not a feature of benign and early-stage borderline epithelial ovarian tumors","volume":"52","author":"Berchuck","year":"1994","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2013.05.021_bb0410","doi-asserted-by":"crossref","first-page":"3985","DOI":"10.1200\/JCO.2007.12.2622","article-title":"Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction","volume":"25","author":"Callahan","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2013.05.021_bb0415","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ygyno.2005.06.065","article-title":"Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers","volume":"100","author":"Finch","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2013.05.021_bb0420","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/path.2091","article-title":"A candidate precursor to serous carcinoma that originates in the distal fallopian tube","volume":"211","author":"Lee","year":"2007","journal-title":"J Pathol"},{"key":"10.1016\/j.ygyno.2013.05.021_bb0425","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.ygyno.2010.10.033","article-title":"Is low-grade serous ovarian cancer part of the tumor spectrum of Hereditary Breast and Ovarian Cancer?","volume":"120","author":"Vineyard","year":"2011","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2013.05.021_bb0430","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1097\/PAS.0b013e3181cf3d79","article-title":"The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory","volume":"34","author":"Kurman","year":"2010","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ygyno.2013.05.021_bb0435","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1038\/modpathol.2011.106","article-title":"Tubal origin of \u2018ovarian\u2019 low-grade serous carcinoma","volume":"11","author":"Li","year":"2011","journal-title":"Mod Pathol"},{"issue":"5","key":"10.1016\/j.ygyno.2013.05.021_bb0440","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/PGP.0b013e318216d447","article-title":"p53 signature and serous tubal in-situ carcinoma in cases of primary tubal and peritoneal carcinomas and serous borderline tumors of the ovary","volume":"30","author":"Leonhardt","year":"2011","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.ygyno.2013.05.021_bb0445","doi-asserted-by":"crossref","first-page":"0756","DOI":"10.1111\/j.1447-0756.2011.01556.x","article-title":"Borderline papillary serous tumor of the fimbriated end of the fallopian tube with peritoneal implants","volume":"37","author":"Ondic","year":"2011","journal-title":"J Obstet Gynaecol Res"},{"issue":"1","key":"10.1016\/j.ygyno.2013.05.021_bb0450","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/PGP.0b013e3181f45f3e","article-title":"The origin of ovarian carcinomas: a unifying hypothesis","volume":"30","author":"Auersperg","year":"2011","journal-title":"Int J Gynecol Pathol"},{"issue":"2","key":"10.1016\/j.ygyno.2013.05.021_bb0455","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1097\/01.AOG.0000227787.24587.d1","article-title":"Clinical behavior of stage II\u2013IV low-grade serous carcinoma of the ovary","volume":"108","author":"Gershenson","year":"2006","journal-title":"Obstet Gynecol"},{"issue":"3","key":"10.1016\/j.ygyno.2013.05.021_bb0460","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.ygyno.2007.11.013","article-title":"Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum","volume":"108","author":"Schmeler","year":"2008","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.ygyno.2013.05.021_bb0465","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ygyno.2009.03.001","article-title":"Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant","volume":"114","author":"Gershenson","year":"2009","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2013.05.021_bb0470","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1002\/cncr.10789","article-title":"Recurrent micropapillary serous carcinoma: the role of secondary cytoreductive surgery","volume":"95","author":"Bristow","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2013.05.021_bb0475","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.ygyno.2012.02.037","article-title":"Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum","volume":"125","author":"Gershenson","year":"2012","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2013.05.021_bb0480","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1002\/cncr.25929","article-title":"Clinicodemographic factors influencing outcomes in patients with low-grade serous ovarian carcinoma","volume":"117","author":"Schlumbrecht","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2013.05.021_bb0485","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S1470-2045(12)70572-7","article-title":"Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: An open-label, single-arm, phase 2 study","volume":"14","author":"Farley","year":"2013","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.ygyno.2013.05.021_bb0490","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1158\/0008-5472.CAN-09-1577","article-title":"Transcriptional pathway signatures predict MEK addiction and response to Selumetinib (AZD6244)","volume":"70","author":"Dry","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.ygyno.2013.05.021_bb0495","doi-asserted-by":"crossref","first-page":"4286","DOI":"10.1158\/0008-5472.CAN-08-4765","article-title":"PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers","volume":"69","author":"Wee","year":"2009","journal-title":"Cancer Res"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825813007543?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825813007543?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,2,22]],"date-time":"2022-02-22T18:52:27Z","timestamp":1645555947000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825813007543"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":98,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["S0090825813007543"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2013.05.021","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Low-grade serous carcinoma: New concepts and emerging therapies","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2013.05.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}